Feb 10 (Reuters) – AstraZeneca on Tuesday forecast profit and sales growth in 2026, betting on demand for its cancer and cardiovascular treatments while the drugmaker pursues massive expansion in the U.S. and China.
The UK’s most valuable listed company forecast total revenue to grow by mid-to-high single-digit percentage at constant currency rates this year, with core profit growth of a low double-digit percentage.
In 2025, sales and profit rose 8% and 11%, respectively.
(Reporting by Pushkala Aripaka and Sri Hari N S in Bengaluru, and Maggie Fick and Bhanvi Satija in London; Editing by Mrigank Dhaniwala)
Comments